March 22, 2018 / 4:34 PM / 6 months ago

BRIEF-Novartis AG Says ‍New Indication Approved Under FDA Priority Review Designation​

March 22 (Reuters) - Novartis AG:

* NOVARTIS DRUG TASIGNA APPROVED BY FDA TO TREAT CHILDREN WITH RARE FORM OF LEUKEMIA

* SAYS ‍IN UNITED STATES, TASIGNA IS NOW INDICATED FOR TREATMENT OF ADULT AND PEDIATRIC PATIENTS ONE YEAR OF AGE OR OLDER WITH NEWLY DIAGNOSED PH+ CML-CP​

* SAYS ‍NEW INDICATION APPROVED UNDER FDA PRIORITY REVIEW DESIGNATION​ Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below